BUZZ-Novavax rises after hedge fund Shah Capital recommends two new director candidates

Reuters04-15

** Shares of Covid-19 vaccine maker Novavax rise 3.5% to $4.43 premarket

** U.S.-based hedge fund Shah Capital recommends appointment of two new independent directors, Suresh Katta and Venkat Peri, to Novavax board

** Shah Capital, which owns approximately 6.7% of the outstanding common stock of Novavax, says low share price reflects the board and management's failure to capitalize on NVAX's many significant competitive advantages and address opportunities in the total market

** "We welcome the perspectives of our shareholders and value their input on our strategy," NVAX said in a statement

** NVAX, one of the most shorted stocks on the Nasdaq, is now trading near its record low

** Up to last close, stock lost more than 53% in the past 12 months

(Reporting by Mariam Sunny in Bengaluru)

((Mariam.ESunny@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment